(0.03%) 5 518.75 points
(0.14%) 39 900 points
(0.07%) 19 765 points
(-0.02%) $81.61
(0.50%) $2.83
(-0.25%) $2 338.60
(0.14%) $29.57
(0.59%) $1 007.70
(0.12%) $0.933
(-0.05%) $10.53
(0.01%) $0.788
(-0.85%) $87.25
Quarter results today
(tns 2024-06-25)
Expected move: +/- 8.21%
3.44% $ 0.619
Live Chart Being Loaded With Signals
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine...
Stats | |
---|---|
Dzisiejszy wolumen | 89 360 |
Średni wolumen | 439 004 |
Kapitalizacja rynkowa | 17.74M |
EPS | $-0.730 ( Q1 | 2024-05-15 ) |
Następna data zysków | ( $-0.320 ) 2024-08-12 |
Last Dividend | $0.250 ( 2012-04-02 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.170 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.81%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-27 | Dewilde Michel | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Braga Damian | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Baxter Jeff | Buy | 70 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Cordeiro Joanne | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Beattie Nell | Buy | 52 500 | Option (Right to Buy Common Shares) |
INSIDER POWER |
---|
-68.01 |
Last 96 transactions |
Buy: 56 847 323 | Sell: 16 390 901 |
Wolumen Korelacja
VBI Vaccines Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
VBI Vaccines Inc Korelacja - Waluta/Towar
VBI Vaccines Inc Finanse
Annual | 2023 |
Przychody: | $8.68M |
Zysk brutto: | $-5.82M (-66.98 %) |
EPS: | $-5.96 |
FY | 2023 |
Przychody: | $8.68M |
Zysk brutto: | $-5.82M (-66.98 %) |
EPS: | $-5.96 |
FY | 2022 |
Przychody: | $1.08M |
Zysk brutto: | $-10.19M (-942.14 %) |
EPS: | $-16.37 |
FY | 2021 |
Przychody: | $631 000 |
Zysk brutto: | $-10.14M (-1 606.81 %) |
EPS: | $-0.270 |
Financial Reports:
No articles found.
VBI Vaccines Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2003-12-18 |
Last Dividend | $0.250 | 2012-04-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.23 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2003 | $0.250 | 14.60% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0.750 | 16.50% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0.250 | 0.02% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
02 Apr 2012 | $0.250 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
12 Jan 2006 | $0.750 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
18 Dec 2003 | $0.250 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -8.82 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.100 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -10.82 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.340 | 0.800 | -3.30 | -2.64 | [1 - 3] |
quickRatioTTM | 0.185 | 0.800 | -3.62 | -2.90 | [0.8 - 2.5] |
cashRatioTTM | 0.162 | 1.500 | -0.209 | -0.314 | [0.2 - 2] |
debtRatioTTM | 0.672 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -99.66 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.04 | 2.00 | -0.681 | -1.362 | [0 - 30] |
freeCashFlowPerShareTTM | -2.06 | 2.00 | -1.031 | -2.06 | [0 - 20] |
debtEquityRatioTTM | -9.28 | -1.500 | -10.00 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | -0.291 | 1.000 | -8.18 | -8.18 | [0.2 - 0.8] |
operatingProfitMarginTTM | -7.56 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.991 | 1.000 | -6.62 | -6.62 | [0.2 - 2] |
assetTurnoverTTM | 0.125 | 0.800 | -2.50 | -2.00 | [0.5 - 2] |
Total Score | -7.71 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.183 | 1.000 | -0.120 | 0 | [1 - 100] |
returnOnEquityTTM | -10.82 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.06 | 2.00 | -0.688 | -2.06 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.04 | 2.00 | -0.681 | -1.362 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00931 | 1.500 | -3.40 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -5.34 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.80 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
VBI Vaccines Inc
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej